Demegen

Demegen's natural and novel peptides are under development for the treatment or prevention of bacterial and fungal infections, including multidrug-resistant strains. Resistance has become a very serious healthcare issue. New solutions are needed.Demegen’s product development is carried out through collaboration or licensing with corporations, universities, and government researchers. The D2A21 peptide is currently in Phase 3 clinical trials for burn wounds. The P113 peptide has completed Phase 2 clinical trials for oral candidiasis. Other potential applications include treatments for dermatological, vaginal, respiratory, and ophthalmic conditions.